{"nctId":"NCT01527370","briefTitle":"Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025)","startDateStruct":{"date":"2012-10-31","type":"ACTUAL"},"conditions":["Herpes Zoster","Shingles"],"count":250,"armGroups":[{"label":"Zoster Vaccine Live","type":"EXPERIMENTAL","interventionNames":["Biological: Zoster Vaccine Live"]}],"interventions":[{"name":"Zoster Vaccine Live","otherNames":["ZOSTAVAX™","V211"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* No fever on day of vaccination\n* Females have a negative pregnancy test and use an acceptable method of birth control, or are postmenopausal\n* Underlying chronic illnesses must be stable\n\nExclusion Criteria:\n\n* History of hypersensitivity reaction to any vaccine component\n* Prior receipt of a varicella or zoster vaccine\n* Prior history of herpes zoster\n* Have recently had another vaccination\n* Have recently received blood products other than autologous blood transfusion\n* Pregnant or breast feeding\n* Use of immunosuppressive therapy\n* Known or suspected immune dysfunction\n* Use of nontopical antiviral therapy with activity against herpesvirus","healthyVolunteers":true,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Geometric Mean Titer (GMT) of Varicella-zoster Virus (VZV) Antibody at 6 Weeks Postvaccination","description":"Antibody titers were measured by VZV-specific glycoprotein enzyme-linked immunosorbent assay (gpELISA).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"149.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"410.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Fold Rise (GMFR) in VZV Antibody Titers at 6 Weeks Postvaccination","description":"GMFR was analyzed as the geometric mean of the ratio of VZV antibody titer (gpELISA units/mL) at postvaccination week 6 over VZV antibody titer (gpELISA units/mL) at prevaccination day 1.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Serious Adverse Events","description":"A serious adverse event is one that results in death, is life-threatening, results in a persistent or significant disability, results in or prolongs hospitalization, results in a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an \"other important medical event\" based on medical judgment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":250},"commonTop":["Injection site erythema","Injection site swelling","Injection site pain"]}}}